Close Menu

RT-PCR

The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.

Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.

Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.

Qiagen will commercialize its research-use-only AdnaTest to detect AR-V7 from liquid biopsies to investigate resistance to drugs for advanced prostate cancer.

The list includes "high throughput DNA sequence analyzer," "DNA genetic analyzer," and "mass spectrometer for clinical multiplex test systems." 

The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.

The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November. 

New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.

The RealStar Zika Virus RT-PCR Kit 1.0 has been listed by the World Health Organization as eligible for procurement agencies and member states.

The company's subsidiary Viracor-IBT can now run the real time, reverse transcriptase-PCR assay for patients meeting clinical or epidemiological criteria for Zika.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.